Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters
The buttoned down execs at Roche don’t traditionally spend much time mourning dead programs or fatal deals. But its brief summary of the pharma giant’s Q4 drug discards is notably silent — even by Roche standards — on two big setbacks on a pair of drugs that once held a key place in its lineup of potential blockbusters.
Last April the pharma giant told me that after burying the lead selective estrogen receptor degraders (SERDs) program from their $725 million Seragon buyout — which also included about a billion in milestones — researchers were turning to another drug they had bagged in the deal. But this morning, their follow-up breast cancer program for RG-6047 — also known as GDC-0927 — got cut.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
